Compass Therapeutics, Inc. (CMPX) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Compass Therapeutics reported revenue of $0, down 100.0% from $850,000 the year before. Net income was -$66.5M. Operating activities generated -$49.1M of cash, leaving -$49.2M of free cash flow. At fiscal year end, Compass Therapeutics held $219.6M in total assets against $22.8M in total liabilities, including $30.6M of cash and equivalents.
Open the full interactive Compass Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Compass Therapeutics Key Stats
| Share Price | $0.86 |
|---|---|
| Market Cap | $160.1M |
| Revenue YoY Growth | -100.0% |
| 52-Week Range | $0.86 – $6.69 |
| Shares Outstanding | 186.8 million (basic, 2026 Q2) |
Compass Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $850,000 | $0 |
| Operating Income | -$27.8M | -$81.9M | -$41.7M | -$50.4M | -$56.6M | -$72.8M |
| Pre-Tax Income | -$29.5M | -$82.2M | -$39.2M | -$42.5M | -$49.4M | -$66.5M |
| Income Tax | $32,000 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$29.5M | -$82.2M | -$39.2M | -$42.5M | -$49.4M | -$66.5M |
| Diluted EPS | -$0.96 | -$1.31 | — | — | — | — |
Compass Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$14.3M | -$15.7M | -$18.3M | -$25.2M |
Compass Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $47.1M | $144.5M | $34.9M | $24.2M | $43.5M | $30.6M |
| Current Assets | $50.2M | $147.1M | $194.8M | $153.9M | $132.8M | $209.8M |
| Total Assets | $51.9M | $153.8M | $199.6M | $156.9M | $140.4M | $219.6M |
| Current Liabilities | $10.1M | $10.6M | $16.2M | $7.8M | $8.9M | $14.0M |
| Total Long-Term Debt | $9.3M | — | — | — | — | — |
| Total Liabilities | $12.0M | $13.7M | $18.0M | $8.3M | $15.2M | $22.8M |
| Shareholders' Equity | $39.9M | $140.1M | $181.6M | $148.5M | $125.2M | $196.8M |
Compass Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$26.8M | -$19.7M | -$34.1M | -$40.6M | -$44.9M | -$49.1M |
| Cash From Investing | $38,000 | -$1.8M | -$151.2M | $27.0M | $46.8M | -$93.3M |
| Cash From Financing | $48.5M | $118.6M | $75.8M | $2.9M | $17.3M | $129.6M |
| Free Cash Flow | -$26.9M | -$21.2M | -$34.3M | -$40.6M | -$44.9M | -$49.2M |
Figures from Compass Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Compass Therapeutics financials page for every line item.
Compass Therapeutics Company Profile
| Ticker | CMPX |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001738021 |
Frequently Asked Questions
What was Compass Therapeutics' revenue in fiscal 2025?
Compass Therapeutics (CMPX) reported revenue of $0 for fiscal 2025.
What is Compass Therapeutics' annual revenue history?
Compass Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $850,000; 2025: $0.
What was Compass Therapeutics' net income in fiscal 2025?
Compass Therapeutics reported net income of -$66.5M for fiscal 2025.
How much free cash flow did Compass Therapeutics generate in fiscal 2025?
Compass Therapeutics generated -$49.2M of free cash flow in fiscal 2025.
What was Compass Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Compass Therapeutics reported revenue of $0.
How many shares of Compass Therapeutics are outstanding?
Compass Therapeutics reported a weighted average of 186.8 million basic shares outstanding in 2026 Q2.
What is Compass Therapeutics' market cap?
Based on its latest closing price, Compass Therapeutics (CMPX) has a market capitalization of about $160.1M.
When does Compass Therapeutics' fiscal year end?
Compass Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Compass Therapeutics headquartered?
Compass Therapeutics lists its business address in Boston, Massachusetts in its SEC filings.
Compass Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →